Are you Dr. Muhsen?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 4 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
6550 Fannin St # SM1101
Houston, TX 77030Phone+1 713-441-5114
Publications & Presentations
PubMed
- 1 citationsImpact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, Noam E Kopmar, Chenyu Lin
Blood Advances. 2024-12-10 - Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant.Ibrahim N Muhsen, Kristen E Shaver, Tao Wang, Mengfen Wu, Premal Lulla
Transplantation and Cellular Therapy. 2024-12-01 - 1 citationsOutcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.Gregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, Chenyu Lin, Simone E Dekker
Journal of Clinical Oncology. 2024-10-17
Press Mentions
Study Shows Long-Term Safety of Genetically Modified Immune Effector CellsMarch 31st, 2022
